Tuesday, November 17, 2026

ASH Preview: The "C" Word

First, some happy personal news about my health. I had a six-week follow-up with the shoulder surgeon today, and I no longer have to wear a sling for my surgically-repaired shoulder. I feel a little more like myself. I have many months of physical therapy ahead of me, but now I can drive and sleep in my own bed and give my wife a hug with both arms. Pretty nice.

As I said in my last post, the abstracts for the ASH meeting were a little bit late, but I did finally get a chance to read them, though it was a quick read. There were some obvious themes. Lots on CAR-T and bispecifics. A good amount of research on biomarkers. Some “real world” studies that look at how treatments are working after they have been approved.

But one thing that really stood out most was one single word: Cure.

It would have been impossible to see this word in an abstract about Follicular Lymphoma in the past, even a year ago. But a few researchers dared to include it this year.

Of course, the mere mention of the word “cure” was made possible by research that was published last spring. Researchers proposed that about 40% of FL patients who had received immunochemotherapy were cured by a 15 year follow up. This caused a great deal of discussion in the FL community. Those of us who were diagnosed before March 2026 were told that Follicular Lymphoma is incurable. Maybe those of you who have been diagnosed in the last six months or so have been told that the disease might be curable. But the idea of a cure has always been something that many of us -- patients and doctors -- did not dare say.

The folks at the Follicular Lymphoma Foundation did an interview with one of the researchers from tat study and wrote about the research. They asked me for my thoughts, which were included in the article. One of my main thoughts was that we have been told for so long that FL is not curable that it's going to take some courage for us -- patients and doctors -- to believe that it might be.

And now, here we are, with at least 3 presentations at ASH in 2026 that explore the idea that Follicular Lymphoma might be curable.

The first one is abstract #3551 Follicular lymphoma (FL) as a curable disease: Late lymphoma-related event rates in immunochemotherapy treated follicular lymphoma are similar to traditionally curable lymphomas (DLBCL and cHL). The researchers for this study looked at their own database, and found that after 10 years, FL patients showed a decrease in the rate of progression of disease and in how frequently patients needed to be treated again. To better understand whether FL was curable, they compared those instances of progression and need for treatment to two other Lymphomas that are considered curable -- Diffuse Large B Cell Lymphoma and classical Hodgkin's Lymphoma. They found that FL patients whose disease did not progress for 10 years had a similar disease path as patients with DLBCL and Hodgkin's Lymphoma after five years -- the amount of time that patients with those diseases are considered cured. The researchers aren't necessarily suggesting that those FL patients were cured, but they do believe that this supports the idea that FL might be curable, since their disease is behaving very similarly to patients with curable diseases.

Another presentation also looks at the idea of curability in FL. In abstract #3578 Using event-free survival at 24 months and baseline FLIPI24 to identify cure in follicular lymphoma, researchers used FLIPI24, a prognostic model, to determine which patients might be curable have curable disease. (I'm not going to get into FLIPI24, but you can read more about it here on your own. Just remember that prognostic models like this predict risk. But it doesn't say anything about you as an individual, and it cannot predict your own individual disease path, good or bad.) The researchers looked at patients who had achieved EFS24, that is, who had received immunochemotherapy and had then gone for 24 months without their disease progressing. They wanted to see if EFS24 patients with a low FLIPI24 score would have an overall survival (as a group) that was roughly the same as the general population.

They found that EFS24 patients with lower FLIPI24 scores at very low lymphoma rated mortality and had an overall survival that was comparable to the general population. Patients with higher risk FLIPI24 scores had a slightly lower overall survival than the general population, though lymphoma-related deaths were uncommon. They believe that FLIPI24 scores may predict which EFS24 patients will have a survival that is in line with the general population. In other words, it might predict that a certain group of patients is functionally cured.

On the other hand, other researchers found that FL prognostic scores cannot identify which patients might be cured. In abstract #1735 Current prognostic indices are unable to identify cured populations with FL: Comparison of three follicular lymphoma prognostic scoring systems in SWOG S0016 with long-term follow-up, researchers tested whether or not three different prognostic scores could possibly predict cure. They tested FLIPI, m7-FLIPI, and FL24Cx to determine how well they could predict success. Again, I won’t get into how these prognostic tools work. They have been shown over the years to have limited use in predicting any single individual patient’s outcomes. With that in mind, the results here are not really a surprise. The researchers found that these tools are good at identifying high risk patients (since they ask questions that determine if a patient is high risk), but they aren’t good at identifying whether or not a patient is cured. That’s just not what they were designed to do.

But the more important point is this – doctors and researchers (and probably patients) are daring to use the “c” word. The idea that FL might be curable, even for a small portion of us, is something that most people in the community would not talk about in the past. And now it’s being talked about.

I’d love to know how many conversations at the ASH meeting are centered on this. The ASCO conference happened just a couple of months after the “curable” research was published, so there wasn’t time to do any kind of research that was related to it. But now there has been time. And we’re starting to see some of it.

It’s going to be exciting to read and watch the commentaries after the meeting is over, to see if curability is a big topic. I’ll certainly pass that along when I see it.

In the meantime, I’ll go back through those FL abstracts and share a few more that I find interesting. Stay tuned.

 

Wednesday, November 11, 2026

Some FL-Related Events to Share

I had hoped to be able to share some ASH abstracts with you by now. If you have been following the blog for a while, you know that ash stands for the American Society for Hematology. They hold their annual conference every year in December, and there is often exciting news about Follicular Lymphoma that gets presented there. I like to look at their abstracts -- the summaries of the presentations -- and share the things that I found most exciting. The abstracts been up online allegedly for a few days. But all I can see are titles, not abstracts. I assume they're coming soon. Once I can access them, I will start writing about them.

While we are waiting, I can give you some information about two webinars offered by the Lymphoma Research Foundation that you might be interested in. The first is called “Update on Follicular Lymphoma,” and it will feature two Lymphoma Rock Stars, Dr. John Leonard and Dr. Reid Merryman. This webinar will take place on Monday, November 16th, from 3:00 to 4:15 PM ET. In some ways, it will be a general overview of FL -- information about diagnosis and staging, first treatment options, relapsed and refractory options, and emerging treatments. At the same time, this general overview will also feature very current information about where we are in our knowledge of our disease. Very up-to-date stuff. You can read more about the webinar and register this link.

The LRF is holding a second webinar next week that's a little more specialized, called “Understanding and Accessing Chimeric Antigen Receptor (CAR) T-Cell Therapy.” I know some of you are very interested in CAR-T treatments, and this webinar was designed for you. The speaker will be Dr. Megan Melody, another Lymphoma Rock Star. This webinar will provide an overview of CAR-T therapy, give information on current clinical trials, talk about barriers to access, and give some time for questions and answers. It should be a very informative session. It's happening next Tuesday, November 17th from 3:00 to 4:15 PM ET. You can read more and register at this link.

While I'm giving you information about sources of information, I really need to give a shout out to my good friends at the Follicular Lymphoma Foundation. The FLF is holding a listening session next week on Friday, November 20th at 10:00 AM ET. (The FLF is headquartered in London, so that's 3:00 PM London time.) The Follicular Lymphoma Foundation has been making a great effort to include input from more patients through their “FL Voices” program. The listening session next week is part of that effort. Here is a description of what they are hoping to hear from people next week:

“When we talk about whether a treatment is working, we often hear about test results, response rates, and other medical measures. But we want to hear about something just as important: what does meaningful benefit from a treatment actually look like to you? Perhaps it’s having more energy, being able to get on with everyday life, having fewer symptoms or side effects, feeling less worried about your lymphoma, or simply having more good days. What matters most will be different for everyone.”

Last I heard, there was still some space available for this session. As an added bonus, the FLF we'll pay you £50 as a recognition of your time. You can read more and register at this link.

As many of you know, I've been doing some work for the FLF for the last couple of years, and I really appreciate everything they are doing to include patients, and I appreciate how hard they work for us. So I hope you will consider getting involved with FL Voices. It benefits all of us.

I hope to have some exciting news from ASH soon. I'll keep looking. In the meantime, consider attending one or more of these events.

 

Wednesday, November 4, 2026

NCCN Guide for Caregivers

 

The National Comprehensive Cancer Network (NCCN) has published a new set of guidelines for caregivers of cancer patients. This is the first time such a guide has been published, at least by the NCCN.

The NCCN has other sets of guidelines. The best known is their sets of guidelines for oncologists. It helps them decide things like which treatment is best to try first, which is best to try after relapse, how often a patient should get a scan, and other decisions that are based on current research. It's similar to the guide from the EHA that I wrote about recently.

The NCCN also publishes a series of guides for patients, each one focused on a different type of cancer, including Follicular Lymphoma. The guides are very good, and are written in clear, easy-to-understand language.

So it is fitting that they would put out a guide for caregivers. And it has been absolutely needed. Given how important caregivers are, this kind of basic support is long overdue. Caregivers are often overlooked when we think about the important things in a cancer patient's life.

In my experience, in my own life and when talking with others, a caregiver is as surprised by a diagnosis as a cancer patient is. For most of us, no one prepared us to be a cancer patients. And no one prepares a caregiver to be a caregiver most of the time. Caregivers have no choice but to kind of make it up as they go along. They have to deal with the physical, emotional, and financial changes to a cancer patient's life, while often trying to live their own lives the same way they had before someone else’s diagnosis. It's a lot to deal with.

That's why I think this guide is so important. And it's not just useful for the caregiver of someone who is newly diagnosed. It's great advice for any caregiver, whether they are helping care for someone who was diagnosed a few weeks ago or many years ago. It's always a good time for a caregiver to get support.

The guide is divided up into several sections. The first one is on what caregiving is. That's important. I think lots of care givers don't realize that they are caregivers. Many of them probably think of a caregiver as someone providing support 24 hours a day. But even regularly helping with small tasks makes someone a caregiver.

Another section discusses the basics of cancer -- what cancer is, some typical types of treatments, some typical side effects that cancer patients deal with. This is one of the places that I think makes this guide so valuable. We all have our vision of what cancer is, but we don't always see it from the perspective of a caregiver. So this section is valuable in helping a caregiver understand what is happening and why. I think it would give many caregivers a bigger picture, which is probably very helpful to them.

Probably the best section (in my opinion) is the one that gives advice on making a caregiving plan. As I said, in my experience, most caregivers are dropped into their role without much time to think about it, and without much time after they begin caregiving to step back and think about the best way to handle things. This section gives some very good practical advice on how to care for someone with cancer day-to-day. It also points out something very important -- how caregiving changes depending on your relationship to the patient. Caring for a spouse is different from caring for a parent or grandparent. It's nice to have specific advice based on those relationship differences.

Another important section talks about the role of the caregiver as part of the larger cancer care team. I think that's incredibly important. We often think of our cancer care team as the healthcare professionals that we deal with -- our oncologist or hematologist, our nurses, hospital and doctors office staff members, various technologists, etc. Discussing the caregiver as an important part of this team puts the caregiver on the same level as these healthcare professionals. And that's where caregivers should be. Many caregivers spend much more time with the cancer patient than any of those healthcare professionals ever will. They know the patient best -- sometimes even better than the patient knows themselves. So discussing the caregiver's role on the same level as the oncologist’s is a really nice recognition of how important the caregiver is. And I hope caregivers who read this guide we'll see that, and believe it.

The last two sections give advice for the actual day-to-day care that a caregiver gives. First is how to take care of the patient. I'm guessing that by the time most caregivers read this, they will already have a very good idea of how to take care of the patient. But they may pick up some good advice anyway.

More important is the section on how a caregiver takes care of themselves. If you've ever spoken to a caregiver, had a deep and honest conversation with them, then you know how physically and emotionally exhausting that role can be. Self-care always comes second for the caregiver, in my experience. So some reminders about self-care are very valuable here. Just things like eating right, getting some exercise, trying to find time for yourself. And that's not always easy for a caregiver. Many of them are working a job while also caring. Free time is taken up by caring for the patient. Self-care comes last. There's a good reminder here that it's OK for the caregiver to get help. But that's not always possible. So it's also a good reminder for us if we are able to give someone else’s caregiver a break when we can.

A couple of interesting statistics from the guide. First is that 1in 4 adults in the United States will be a caregiver at some point. And the length of time they act as a caregiver averages about 5.5 years. As cancer treatments become better, and people live longer lives, the need for caregiving has become even more important.

One more point that the guide makes: caregivers aren’t perfect. And they don't need to be. We all have bad days, caregivers included. There are things we simply cannot do. The help that we can give sometimes has to be good enough.

As I have been reading this guide, I have been thinking about my own recent experience. It's been a long time since I needed help that was related to my status as a cancer patient. But I'm dealing with a shoulder injury and recovery from surgery right now, as I write this. My wife has been my chief caregiver for the last few weeks. And even though I'm getting stronger every day and more independent, there is still much that she needs to do for me. I see the time she puts in, not just at helping me with things like putting my socks on my feet and tying my shoes, and driving me to physical therapy or anywhere else I need to go. But she's also taken on a lot of the work that I have often done for us, like cooking meals, dealing with our dog, going to the grocery store, etc. It's frustrating for me to need the help,  though she does it without complaint, even though she’s dealing with her own health issues. So I have a very good reminder day-to-day of just how important caregivers are to patients. And I have a good reminder to make sure I say thank you.

If you have a caregiver in your life, I hope you'll show them this guide. If you know other patients, I hope you'll share it with them, so they can share it with the caregivers in their lives. They are such an important part of our care team. And even the small way of supporting them, by sharing a guide that might make their lives just a little bit easier, might be a nice way to say thank you.


Thursday, October 29, 2026

Updated European Guidelines for Treating FL

The European Hematology Association just published its updated Follicular Lymphoma guidelines in the journal HemaSphere. The guidelines are pretty comprehensive. They include recommendations for diagnosis, staging, first treatment, second treatment, and treatments after relapse. But they also include information about survivorship, which is pretty nice.

The guidelines are slightly different, I think, from those in the United States. They also are based on very recent phase III clinical trial results. So they are about as up-to-date as you can find.

I'm not going to go through all of their recommendations. I think you should read them for yourself. Here's the link again. But there are a few things from the article that I find interesting and worth highlighting.

Before I go on, this is a very good time to remind you all that I am not a medical doctor. I'm not a cancer biologist. I’m just a Cancer Nerd -- a patient with a blog who likes to read a lot. What I write is not medical advice. The best person to talk to about your disease is your own oncologist. But I hope sharing some of this makes that conversation a little easier. That's always the goal here.

One thing that I really liked to see in the abstract was this: “The median overall survival at diagnosis now likely exceeds 20 years.” That's pretty remarkable. When I was diagnosed almost 19 years ago, the literature on FL put the median survival at 8 to 10 years. We've more than doubled it in that time. I'm going to write more about that soon.

But for now here are a few thoughts from EHA guidelines. First is diagnosis. The guidelines say that about 85% of FL patience have the t(14;18) gene mutation. There are other common mutations as well, but they don't recommend testing for them, because there still really isn't enough information about them to know if it's worth knowing that a patient has a KMT2D mutation, for example. I've said this before -- there's still lots of research that needs to be done on biomarkers for FL.

In their discussion about first treatments after diagnosis, the guidelines still recommend active surveillance (or watch and wait) for asymptomatic, low tumor burden disease. They also suggest straight Rituxan is acceptable, though this treatment does not increase Overall Survival when compared to watching and waiting.

I found this especially interesting: For patients who do need treatment, Iimmunochemotherapy is the recommendation. This could be Bendamustine or CHOP along with Rituxan or Obinutuzumab. I think it’s interesting because there is so much discussion these days about “moving on” from traditional chemotherapy.  They do mention R-squared as an option for a first treatment, but looking at the research, they say the clinical trials for R-squared showed it was comparable to Immunochemotherapy but not better. The guidelines say that Rituxan (or Obinutuzumab) maintenance is an option after Immunochemotherapy. Research shows that maintenance therapy extended Progression-Free Survival, but it did not increase Overall Survival. Patients who are susceptible to infection should not receive maintenance since it lowers immunity.

As for treatment at relapse, the guidelines recognize that there are many choices. Patients with asymptomatic disease can go back to watching and waiting. But for those who need treatment, the guidelines recommend R-squared. They also recommend considering R-Squared plus either Tafasitamab or Epcoritamab. Both of these combinations showed better response rates and longer PFS then just R-squared.

For patients who progress within 24 months after immunochemotherapy, the so-called POD24 group, options include CAR-T, though CAR-T after Bendamustine may be less effective because the Bendmustine messes with the T cells that are needed for CAR-T. The guidelines mention Stem Cell Transplants, which are still used, but much less frequently than in the past. There are many more options these days.

For patients who need a third line of treatment, the guidelines suggest Bispecific Antibodies, CAR-T, Zanubrutinib, and R-squared combinations. While there are several versions of Bispecifics and of CAR-T, the guidelines don’t recommend any particular version of either. They all have strengths and weaknesses that need to be considered when dealing with each individual patient.

The last section is on Survivorship. If you've been reading the blog for the last few years, you know Survivorship is becoming more and more important to me. Survivorship is what happens after treatment it's “finished.” The guidelines point out that about 90% of FL patients have a response to their first treatment. Most patients should see their oncologist  for two years after they are finished with treatment. After that, they can see the oncologist less often. Survivorship after treatment should focus on some common long-term side effects and issues, including infections, vaccinations, cardiovascular issues, secondary cancers, fatigue, and psychological well-being. I'm very glad they included that last one. I continue to believe that cancer patients’ and survivors’ mental health is greatly ignored. Other issues that FL patients have to deal with during Survivorship include employment, financial issues, and anxiety about the disease returning. All true, and I’m impressed tat they are acknowledged in the guidelines.

As I said, I really encourage you to look at the guidelines yourself. That's especially true if you live in Europe. These guidelines are a little different from what is often recommended in the United States. And it's important to remember, as the guidelines point out, that not every treatment is available or has been approved in every country in Europe. So these guidelines are just that -- guidelines. A conversation with your doctor that includes a discussion of your own goals for treatment, your overall health, your financial picture, and your emotional state is really important. Choosing a treatment should be more than just picking the treatment with the highest numbers. There's so much more to be considered.

I did find it very interesting to read these guidelines, and to think back about what was available to me 19 years ago. Guidelines like this are constantly evolving, as they should, because the treatment landscape is constantly evolving. I think it's really interesting that treatments like Bispecifics and CAR-T, which get so much attention here in the US, are not recommended until much later in the process here. I don't think that says something bad about the European Hematological Association. I think it says something more about the oncology journalism in the United States. Doctors get very excited about those treatments, with good reason. But it's good to see that in the real world, they are one (or two) of many different types of treatments.

And that's a good thing. We have lots of options. And as these guidelines show, we have lots of very smart people who look at the very big picture to help determine which treatments, and in which order, are likely to be most effective for us.

I also think it can be a bit overwhelming to look at all of these treatments available to us and wonder how we would ever choose which one to use. But thankfully we don't have to, and it's because of those smart people.

Remember, talk to your doctor. Have those conversations even before you need to.

More soon.